CVRx Announces First Patient Enrollment in Landmark BENEFIT-HF Heart Failure Trial
CVRx, Inc. has announced the enrollment of the first patient in the BENEFIT-HF trial, a large-scale study evaluating the Barostim therapy in heart failure patients. The trial aims to enroll 2,500 patients across 150 centers in the U.S. and Germany, assessing the effectiveness of Barostim in a broader heart failure population. This could potentially triple the patient population indicated for Barostim, thus broadening access to the therapy.
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart – a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson.